Journal of Oncology Pharmacy Practice最新文献

{"title":"Assessment of analgesics and alternative approaches in cancer pain management: A cross-sectional study.","authors":"Syed Hassam Ali Sami","doi":"10.1177/10781552251381791","DOIUrl":"https://doi.org/10.1177/10781552251381791","url":null,"abstract":"<p><p>BackgroundPain is highly prevalent in cancer and requires proper assessment and management. The evaluation is important particularly in cancer pain management, to make some improvement in prescribing analgesics and alternative approaches in the hospitals to enhance the quality of life of cancer patients.ObjectiveThe objective of this study was to assess analgesics and alternative approaches in cancer pain management and compare current prescribing practices with WHO guidelines for pain management.MethodsA cross-sectional study was conducted at PIMS, Islamabad. Data of 203 patients was analyzed. Patients' age, gender, diagnoses, pain intensity, analgesics, and alternative approaches prescribed, were recorded. All these variables were summarized using descriptive statistics and comparison between variables done by using Chi-square test.ResultMost patients were aged 26-35 years (29%), and 76% had blood cancer. Pain intensity was moderate in 51% of patients. Weak opioids (tramadol 69%, codeine + paracetamol 68%) were the most prescribed drugs. No strong opioids were used. Only 3% of patients received alternative therapies (physiotherapy, radiotherapy). About 54% of prescriptions were consistent with WHO pain management guidelines. The majority of pain management strategies did not align with WHO's analgesic ladder, particularly for severe pain cases, where strong opioids were noticeably absent. Significant associations were found between cancer stage, pain intensity, and type of analgesics used (p < 0.05).ConclusionThis study found that the pain in cancer patients at PIMS is often undertreated, with a heavy reliance on weak opioids and low use of strong opioids and alternative therapies. Limited use of strong opioids reflects systemic barriers including restrictive regulations, high costs, and limited availability. Improved access to opioids, guideline-based prescribing, and integration of palliative care are essential to ensure effective pain relief for cancer patients in Pakistan.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251381791"},"PeriodicalIF":0.9,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the toxicity and clinical outcomes of doxorubicin, cyclophosphamide, and taxane-based chemotherapies in women with breast cancer in Bangladesh.","authors":"Md Shalahuddin Millat, Md Saddam Hussain, Arafat Miah, Md Abdul Barek, Mohammad Sarowar Uddin, Mahmuda Ferdous, Md Abdul Aziz, Md Mahmudul Hoque, Md Saiful Islam, Mohammad Safiqul Islam","doi":"10.1177/10781552251377418","DOIUrl":"https://doi.org/10.1177/10781552251377418","url":null,"abstract":"<p><p>BackgroundIndividuals receiving chemotherapy for breast cancer frequently experience severe drug reactions, which exacerbates safety issues such as decreased quality of life, prolonged treatment, and reinforcement of negative emotions associated with therapy. The emergence of these issues is especially devastating in developing countries like Bangladesh, where the medication's safety profile is inadequate. The goal of the current study was to assess the real-time toxicological and clinical outcomes of doxorubicin, cyclophosphamide, and taxanes treated breast cancer patients in Bangladesh.MethodsAbout 151 breast cancer patients were recruited from the National Institute of Cancer Research and Hospital (NICRH), Dhaka, Bangladesh, where 132 and 19 patients received doxorubicin-cyclophosphamide-paclitaxel and doxorubicin-cyclophosphamide-docetaxel chemotherapy regimen, respectively. Clinical responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), whereas chemotherapy-associated toxicities were graded according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).ResultsThe most common non-hematological adverse events reported across the both treatment regimens were nausea, vomiting, diarrhea, and fatigue, along with several other symptoms. Anemia (61.93%) emerged as the most common hematological toxicity, followed by conditions like neutropenia (21.8%), leukocytosis (19.87%), and lymphocytosis (18.54%). Patients also experienced various organ and tissue specific toxicities, with liver, kidney, and heart complications being notable. These side effects contributed to significant health challenges during the course of treatment. Unfortunately, a number of patients passed away, with most of the deaths occurring within five years of their cancer diagnosis.ConclusionsIn conclusion, breast cancer patients in Bangladesh are experiencing numerous non-haematological and haematological side effects, which impacting overall patient wellbeing that contributed to notable challenges including death. Personalized treatment approach could therefore be helpful to mitigate side effects and improve overall patient's experience.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251377418"},"PeriodicalIF":0.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia.","authors":"Dat Ngo, Jose Tinajero, Jianying Zhang, Anthony Stein, Guido Marcucci, Amandeep Salhotra, Vinod Pullarkat, Karamjeet S Sandhu, Brian J Ball, Hoda Pourhassan, Paul Koller","doi":"10.1177/10781552241276547","DOIUrl":"10.1177/10781552241276547","url":null,"abstract":"<p><p>IntroductionMidostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are commonly used in AML and are known to interact with anti-cancer drugs such as midostaurin through the CYP3A pathway. However, there are no midostaurin related dose modifications recommended with strong CYP3A inhibitors.MethodsWe retrospectively reviewed 40 patients between 2017-2022 and compared efficacy and safety outcomes in patients who received azole antifungals concurrently to those who did not receive an azole or received it sequentially to midostaurin for treatment of FLT3m AML.ResultsMedian age of both groups was approximately 55 years and 70% of patients harbored FLT-3 internal tandem duplication mutations. Most patients in the concurrent arm were on either posaconazole (33%) or isavuconazole (50%) for antifungal prophylaxis and micafungin (72%) for the sequential/no azole arm. Overall CR/CRi rate with concurrent versus sequential/no azole were 72% and 77%, and non-hematologic grade 3 toxicities were 22% and 40% (<i>p</i> = 0.21), respectively. Rates of dose reductions (6% vs. 0%, <i>p</i> = 0.26) and held doses (17% vs. 14%, <i>p</i> = 0.79) were not different between concurrent and sequential/no azole. There were no differences in the rates of new fungal infection during induction between the two groups.ConclusionAzoles given concurrently or sequentially with midostaurin were found to be equally safe and effective in the treatment of newly diagnosed FLT3 AML. Additional confirmatory studies are needed due to our limited sample size.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1071-1075"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population.","authors":"Hina Raza, Mariyam Javaid, Wajiha Rehman, Sana Rafiq, Zermina Rashid, Rahat Shamim, Abdolelah Jaradat, Mohamed Deifallah Yousif","doi":"10.1177/10781552241275948","DOIUrl":"10.1177/10781552241275948","url":null,"abstract":"<p><p>Introduction5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat various types of cancers. Although widely used, it has consistently been attributed to cardiotoxicities after administration. The purpose of this study was to assess the parameters and predictors of cardiotoxicities associated with various 5-FU-based chemotherapeutic protocols in patients with GI/colorectal cancer, as well as the correlation of these cardiotoxic events with age, sex, cumulative dose, and risk factors such as obesity, hypertension, and family history of cardiac diseases.MethodsA prospective study consisting of 396 patients of both sexes was conducted in the oncology ward of Nishtar Hospital in Multan, Pakistan. Patients were grouped according to the therapeutic protocol they received (5-FU monotherapy or in combination, with different dosing regimens). Electrocardiography and serum troponin levels were used to assess 5-FU-induced cardiotoxicity. In cases where cardiotoxicity was detected, 5-FU treatment was interrupted; nitroglycerin, nitrates, and calcium channel blockers were administered; and cardiac monitoring was initiated. 5-FU was discontinued in all cases of acute myocardial infarction.ResultsOf the 396 patients, 28.5% reported different cardiotoxic symptoms after receiving various 5-FU-containing protocols. 35% had anginal pain, 13% suffered a myocardial infarction, 11% developed hypertension, and 10% presented heart failure. Patients receiving 5-FU combination therapy showed cardiotoxic events that were significantly different from those on 5-FU monotherapy. Based on the ECG results, only the QTc-d interval increased significantly (p < 0.001) after therapy. 68% of the patients had troponin levels > 2 ng/mL at the end of treatment.ConclusionsPre-existing cardiac diseases, treatment duration, smoking, and obesity were found to be influential components in the development of cardiotoxicity, and patients with cancer should be closely monitored during 5-FU chemotherapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1037-1045"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global oncology pharmacy service levels and knowledge requirements: A review by the International Society of Oncology Pharmacy Practitioners.","authors":"Marissa Ryan, Evelyn Handel Zapata, Irene Weru, Annette Netty V Cracknell","doi":"10.1177/10781552251332199","DOIUrl":"10.1177/10781552251332199","url":null,"abstract":"<p><p>IntroductionThe International Society of Oncology Pharmacy Practitioners (ISOPP) has over 3500 members across 110 countries. ISOPP's strategic objectives are membership engagement, empowering the global oncology pharmacy community, facilitating professional development, and advocating for advancement. Aligning with these objectives, this research aimed to describe global oncology pharmacy service provision and knowledge requirements.MethodsFifty-three ISOPP global oncology pharmacy leaders from 45 countries were invited to complete a survey. Questions in the survey explored whether protected titles existed for oncology practitioners, the oncology pharmacy service levels that were being offered from the seven levels proposed, knowledge requirements for these levels, and access to education. Free text comments were analyzed for context or themes and described descriptively. Based on responses, the proposed service levels and required knowledge were reviewed to establish the ISOPP Oncology Pharmacy Service Levels.ResultsResponses from 35 countries were received. Thirty-five (100%) participants reported that pharmacist was a protected title, and 18 (51%) participants reported that pharmacy technician was protected. However, oncology pharmacist was a protected title in one (3%) country only, Singapore. Fourteen (40%) countries delivered all seven levels, and 35 (100%) countries delivered at least three levels. Some participants reported being unfamiliar with some of the survey terminology; this information was used to clarify the wording of the service levels and knowledge requirements.ConclusionThis global review of oncology pharmacy services will aid professional development and advancement, by connecting countries with mentoring opportunities and resources, and establishing a benchmark for the future growth of services globally.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1104-1114"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical considerations for pharmacists regarding the use of radiopharmaceuticals in oncology.","authors":"Heather Corello, Stephanie Pang, Hannah Bustillos, James W Velez","doi":"10.1177/10781552251359187","DOIUrl":"10.1177/10781552251359187","url":null,"abstract":"<p><p>BackgroundRadiopharmaceutical therapy encompasses the targeted delivery of radioactive atoms to sites of malignancy within the body and represent a rapidly growing area of drug development in oncology. In comparison to cytotoxic chemotherapy, radiopharmaceutical therapy has the potential for fewer adverse effects and is able to produce a strong anti-cancer response in a wide range of malignancies.ObjectiveThis article reviews radiopharmaceutical therapy mechanisms and discusses four well-established agents that are used in clinical practice, their place in therapy, safety, utilization of concomitant therapies, and contact precautions for each agent.SourcesInformation presented in this article is sourced from the available literature on radiopharmaceutical development, oncology clinical practice guidelines, clinical trial results, and package insert data.SummaryRadiopharmaceuticals possess significant differences in drug mechanism and design from that of traditional cytotoxic chemotherapy agents. The basic functional and structural variances in combination with isotope selection drive the clinical efficacy of radiopharmaceutical therapy and inform pharmacists of the important considerations of each therapy's distribution, off-target effects, clearance, and toxicities.ConclusionThe drug and safety information presented in this article pertaining to select radiopharmaceuticals is pertinent to an oncology pharmacist's role in patient care as radioactive therapies continue to expand the complexity of the oncology treatment landscape.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1165-1173"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab deruxtecan: An antibody-drug conjugates for non-small cell lung cancer.","authors":"Nahida Siddiqui, Gojuvaka Sravanthi, Kanugonda Jashwanth Kumar Reddy, Kummarikunta Salomi, Tadikonda Rama Rao, V V Rajesham","doi":"10.1177/10781552251383762","DOIUrl":"https://doi.org/10.1177/10781552251383762","url":null,"abstract":"<p><p>ObjectivesThis review compiles to provide an overview of non-small cell lung cancer (NSCLC) and the therapeutic rationale for antibody-drug conjugates (ADCs), followed by a summary of current evidence highlighting the efficacy, safety, and adverse event management of trastuzumab deruxtecan (T-DXd) in HER2-mutant metastatic NSCLC.Data SourcePUBMED, ClinicalTrials.gov, and Google Scholar were searched to retrieve relevant clinical studies including randomized controlled trials, non-randomized studies, observational studies, and real-world evidence from its approval to July, 2025 for the treatment of patients with HER2-mutant metastatic NSCLC received prior systemic therapy. The search strategy was guided by the target therapeutic area, intervention type, and population studied.Data SummaryT-DXd, a HER2-targeted ADC and second line treatment, has shown significant clinical benefit in HER2-mutant metastatic NSCLC, as evidenced by key clinical trials (NCT04644237 and NCT04644237) demonstrating high objective response rates (ORRs) and disease control rates (DCRs). Although it exhibits a manageable safety profile, interstitial lung disease (ILD) remains a notable adverse event (AE), with improved tolerability observed at the lower dose of 5.4 mg/kg. Moreover, multidisciplinary Strategies are also used to manage T-DXd associated AEs. Additionally, ongoing trials are evaluating the combination of T-DXd with immunotherapy and targeted agents to optimize safety outcomes and efficacy in high-risk NSCLC populations.ConclusionsT-DXd at 5.4 mg/kg offers substantial efficacy with better tolerability than 6.4 mg/kg. Incorporating AE mitigation, real-world insights, and combination trial data may further optimize its safety and clinical benefit in this biomarker-defined population.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251383762"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of sunscreen in the prevention of skin cancer.","authors":"John P Micha, Randy D Bohart, Bram H Goldstein","doi":"10.1177/10781552251327596","DOIUrl":"10.1177/10781552251327596","url":null,"abstract":"<p><p>ObjectiveDespite the reported benefits of sunscreen use in preventing skin cancer, the overall protection from melanoma and non-melanoma skin cancers putatively reflects the frequency of use and sunscreen type. Herein, we review the current knowledge regarding sunscreen's effectiveness at averting the development of skin cancers.Data sourcesWe conducted an extensive PubMed search comprising several review articles on the topic of sunscreen use and prevention of skin cancer, with specific terms that included sunscreen and usage, skin cancer, and sunscreen side effects.Data summarySeveral observational, cohort studies and randomized controlled trials have underscored the benefits of sunscreen in forestalling skin cancers. In particular, the incidence of melanoma and squamous-cell carcinoma is reduced, although the effect of sunscreen on basal-cell carcinoma is relatively less pronounced.ConclusionsThe implications from this study indicate that sunscreen reduces the incidence of melanoma and non-melanoma skin cancers although deriving the intended effect is contingent upon the type of sunscreen and adherence to the recommended guidelines. The primary side effects from sunscreen include dermal irritation and rash; and since there is some indication that UV filter-based sunscreens may harbor carcinogenic properties, clinicians should advise their patients on the type of sunscreen, not to mention the frequency of use.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1145-1149"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suzetrigine: A potential alternative for palliative pain management in Pakistan's opioid-restricted healthcare system.","authors":"Mahmood Memon, Sahil Kumar, Manoj Parkash, Mahek Bansari, Muaaz Mahmood, Anosh Khowaja, Sahir Bansari, Farina Fatima Siddiqui, Ayesha Naseer, Ayesha Almas, Muhammad Momin Khan","doi":"10.1177/10781552251340330","DOIUrl":"10.1177/10781552251340330","url":null,"abstract":"<p><p>BackgroundPalliative care aims to improve the quality of life for patients with terminal illnesses by addressing physical, psychological, and social needs. However, only 14% of individuals globally who need palliative care receive it. In Pakistan, the availability is critically low, with a palliative care-to-population ratio of 1:90 million. Access to strong opioids for pain relief is severely restricted, with only 2% of terminally ill patients receiving adequate analgesia. These limitations, driven by concerns over opioid misuse and regulatory restrictions, highlight the urgent need for effective, accessible non-opioid alternatives. Suzetrigine, a novel NaV1.8 channel inhibitor, may offer a promising solution.MethodsThis brief review summarizes clinical trial data from multiple Phase 2 and Phase 3 studies evaluating the efficacy and safety of Suzetrigine in managing acute and chronic pain. Primary endpoints included the time-weighted sum of pain intensity difference over 48 hours and weekly average pain score reductions assessed using the numeric pain rating scale. The implications of these findings were contextualized in the setting of Pakistan's opioid-restricted palliative care landscape.ResultsSuzetrigine demonstrated statistically and clinically significant analgesic effects in trials involving postoperative pain, lumbar radiculopathy, and diabetic neuropathy. The drug was well-tolerated, with adverse events such as nausea, headache, and constipation being mild and infrequent.ConclusionSuzetrigine presents a viable non-opioid analgesic alternative for palliative care in Pakistan, where regulatory and systemic barriers limit opioid access. Its introduction could enhance pain management, reduce opioid-related harms, and support the development of a safer, more accessible palliative care model.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1188-1190"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sjogren's syndrome due to immune checkpoint inhibitors (ICIs): Insights from a single-institution series and systematic review of the literature.","authors":"Abram Soliman, Ruba Hassan, Ion Codreanu, Steven C Plaxe, Constantin A Dasanu","doi":"10.1177/10781552241271753","DOIUrl":"10.1177/10781552241271753","url":null,"abstract":"<p><p>IntroductionCareful adverse event assessment and management are important when prescribing immune checkpoint inhibitors (ICIs) to cancer patients. Iatrogenic Sjogren's syndrome is a relatively rare immune-related adverse event (irAEs) that affects the moisture-producing glands.MethodsWe describe a series of four patients who developed Sjogren's syndrome while being treated with ICIs at a community cancer center in Southern California, USA (1/1/2017-12/31/2023). Patient, drug and disease-related data were collected by retrospective chart review. A systematic search of the PubMed database was performed to identify similar cases in the literature (1/1/2016-12/31//2023).ResultsOf 224 cancer patients at our center treated with ICIs, four (1.8%) developed iatrogenic Sjogren's syndrome. All of our patients were male; three received PD-1 inhibitors (nivolumab, pembrolizumab) and one received the PD-L1 inhibitor atezolizumab. The median time to development of Sjogren's syndrome was 24 weeks (range, 8-36 weeks); dry mouth symptoms were more prominent than dry eye symptoms. None of the patients had elevated SS-A, SS-B or antinuclear antibodies. One patient developed multiple tooth cavities and had several extractions, due to severe xerostomia. Management of all patients was primarily symptomatic. Two cases were irreversible; one was reversible and the 4^th case is undermined as he is still on ICI therapy. Our systematic review of the literature identified 80 cases in five articles. Incidence of xerostomia was twice of that of xerophthalmia. The male/female ratio was 1.5:1. SS-A, SS-B, or antinuclear antibodies were found in only 9% of patients. Steroids were reported to have had only a limited role in management.ConclusionsThe incidence of Sjogren's syndrome due to ICIs in our center was 1.8%. Details of clinical course and management in these patients are presented. Caring for patients with ICI-related Sjogren's syndrome is facilitated by a multidisciplinary effort including oncologists, otolaryngologists, dentists, ophthalmologists and rheumatologists. Expanding the knowledge base pertaining to iatrogenic Sjogren's syndrome in patients on ICIs will be helpful in promoting early detection and treatment, and improving outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1029-1036"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}